EGFR and non-small cell lung carcinoma: Numerous EGFR tyrosine kinase domain inhibitors (TKIs) and vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR) neutralizing antibodies have been developed and approved for the treatment of NSCLC [7].